BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$90.02 USD
0.00 (0.00%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $90.00 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$90.02 USD
0.00 (0.00%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $90.00 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
Zacks News
5 Great Biotech Stocks to Buy Now
by Swarup Gupta
Biotechs have stabilized and still offer the potential to deliver substantial returns.
BioMarin's Hemophilia Candidate Included in PRIME Initiative
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that BMN 270, being evaluated for the treatment for severe hemophilia A, has been granted access to Priority Medicines (PRIME), a regulatory initiative by the European Medicines Agency (EMA).
Is BioMarin (BMRN) Well Poised for Growth in 2017?
by Zacks Equity Research
We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
3 Overlooked Drug Stocks to Watch Out for in 2017
by Arpita Dutt
As we start the New Year, here is a look at 3 drug stocks that have not been in the news much but have been witnessing upward estimate revisions and sport a strong Zacks Rank.
BioMarin (BMRN) Raised to Buy: Should You Add the Stock?
by Zacks Equity Research
The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).
New Strong Buy Stocks for October 24th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
New Strong Buy Stocks for October 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
New Strong Buy Stocks for October 6th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
5 Biotech Stocks to Bet on This Earnings Season
by Zacks Equity Research
The happening biotech sector should be a good bet for investors.